ADC Therapeutics Announces Updated Data From LOTIS-7 Phase 1b Open-Label Clinical Trial Evaluating Safety And Efficacy Of ZYNLONTA In Combination With Bispecific Antibody Glofitamab In r/r DLBCL Patients

ZYNLONTA® in combination with glofitamab (COLUMVI®) demonstrated an 89.8% ORR and 77.6% CR across the 49 efficacy-evaluable patients with a minimum of 6 months of follow-up

Combination continues to be generally well-tolerated with a manageable safety profile

LOTIS-7 trial is on track for complete patient enrollment in 1H 2026; plan to share full data at a medical meeting and submit for publication by end of 2026

Company to host conference call today at 8:00 a.m. EST

LAUSANNE, Switzerland, Dec. 3, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE:ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced updated data from the LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and efficacy of ZYNLONTA® in combination with the bispecific antibody glofitamab (COLUMVI®) in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL). The updated data is based on investigator assessment and reflects the 49 efficacy-evaluable patients with a minimum of 6 months of follow-up from treatment initiation.